Viability of European cross-border access opportunities to streamline access to ATMPs
In December 2021, the Regulation on Health Technology Assessment (HTA), as originally proposed by the European Commission, was adopted. The Regulation...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Walter Colasante is a vice president in the Life Sciences Practice at CRA. He has experience in both the pharmaceutical and consulting industries. Walter has experience across a range of different therapeutic areas, most notably oncology, CNS, and rare diseases.
Prior to his role at CRA, Walter was a senior principal at a global life sciences company, consulting primarily in global market access strategies and EU parallel trade. In the pharmaceutical industry, he has held several clinical research positions. At a pharmaceutical corporation, he was International Brand Director for its retinal products franchise. He is fluent in Italian and French.